ACD856
ACD-856 · NeuroRestore ACD856
Last updated
At a glance
ACD856 is an investigational compound being studied for disorders that affect cognition. It enhances neurotrophin signaling, with laboratory and animal findings supporting further research into neuronal function. Early studies in healthy adults describe short-term tolerability and drug exposure, while cognitive benefits remain unestablished in these sources. The dosage sections distinguish published trial designs from enhancement regimens, which the reviewed evidence does not establish.
Overview
ACD856 is a small-molecule positive allosteric modulator of Trk receptors from AlzeCure's NeuroRestore platform. Its research interest centers on enhancing NGF/TrkA and BDNF/TrkB signaling. It is distinct from its predecessor ACD855 and from the neurotrophins themselves.
The evidence separates into preclinical mechanism studies and early healthy-volunteer safety/PK trials. Neither establishes an enhancement regimen or cognitive benefit in people. The single-dose study and multiple-dose study describe clinical trial material; they do not authenticate other products sold under the ACD856 name.
AlzeCure reported additional Phase Ib results in June 2026 and announced a QuantumCell agreement in July. These are sponsor development updates, not peer-reviewed evidence of patient benefit.
How ACD856 works
Neurotrophin Signaling#
ACD856 is described as a Trk receptor positive allosteric modulator. Dahlström et al. investigated enhancement of NGF/TrkA and BDNF/TrkB signaling. ACD856 is a small molecule, not an administered BDNF or NGF protein.
Preclinical Findings#
The 2023 work examined signaling, neurite outgrowth and experimental neuronal injury. Its laboratory and animal findings support further investigation; they do not establish disease modification or cognitive improvement in patients.
"The pharmacological effect of ACD856 was tested in recombinant cell lines, primary cortical neurons, or animals." Parrado Fernandez C et al., 2023
Human Pharmacodynamic Evidence#
The multiple-dose study detected ACD856 in cerebrospinal fluid and observed qEEG changes. These support CNS exposure and a pharmacodynamic effect. They are not measurements of improved memory, focus or mood.
Protocol
Published Trial Doses#
These amounts describe study designs and clinical formulations. They are not beginner, intermediate or advanced enhancement tiers.
| Study | Administration | Duration | Participants |
|---|---|---|---|
| IV microdose | 0.100 mg once | Single exposure | Six healthy men |
| Single ascending oral doses | 1–150 mg | Single exposure | 56 healthy adults |
| Multiple ascending oral doses | 10, 30 or 90 mg once daily | Seven days | 24 healthy adults; six active and two placebo per cohort |
Sources: Nilsson et al., 2024 and Önnestam et al., 2023.
The reviewed sources do not establish a complete focus, memory, mood, recovery or aesthetics protocol. No use-case dosing presets are supplied.
Cycle length & outcomes
Trial Duration and Cycle Limits#
The published multiple-dose trial followed seven daily administrations in healthy adults. Its duration is a feature of that study, not a maximum safe exposure or a validated enhancement cycle.
No source in this review establishes a loading phase, taper, off-cycle interval or long-term dosing schedule. The approximately 20-hour elimination half-life describes plasma exposure; it does not establish the duration of any cognitive effect.
Risks & mistakes
Short-Term Findings#
The small, short healthy-volunteer studies reported favorable tolerability. Their size and duration cannot exclude rare harms or establish long-term safety.
"Treatment with ACD856 was well tolerated with no serious adverse events." Önnestam K et al., 2023
Safety Gaps#
The reviewed evidence does not establish reproductive, pregnancy, lactation, pediatric or long-duration safety, or a validated combination-safety profile. These are evidence gaps, not proof that particular adverse effects occurred. Men and women participated in the multiple-dose study; that does not resolve reproductive safety.
The sources do not establish a PCT regimen, prophylactic ancillary requirement or routine laboratory-monitoring schedule for ACD856. Favorable early tolerability should not be read as a general safety guarantee.
FAQ — ACD856
Research & citations
3 studies cited on this page.
Conclusion
ACD856 has a defined research rationale as a Trk receptor modulator and published early safety and pharmacokinetic observations in healthy adults. The sources reviewed here do not establish cognitive efficacy, long-term safety or an enhancement protocol.
The useful distinction is between the studied clinical material, preclinical findings and unverified extrapolation. Trial dose cohorts, biomarker changes and sponsor announcements each answer different questions; none alone supplies a validated nootropic regimen.